Literature DB >> 2403840

Tumor growth inhibitory activity of a lymphocyte blastogenesis inhibitory factor.

K Sugimura1, T Ohno, S Fukuda, Y Wada, T Kimura, I Azuma.   

Abstract

A lymphocyte blastogenesis inhibitory factor (LBIF) has been characterized as an immunoregulatory molecule, especially on the T-lymphocyte proliferation. Using fast protein liquid chromatography-purified LBIF, we examined the effect of LBIF on the proliferation of various 18 tumor cell lines in vitro in comparison with those of interferon-alpha, interferon-gamma, tumor necrosis factor-alpha, transforming growth factor-beta 1, or interleukin 1 alpha/beta. We showed here that LBIF strongly inhibited the proliferation of various tumor cell lines irrespective of cell lineage or species. LBIF was effective on a wider spectrum of tumor cell lines than other cytokines tested here. The inhibition resulted from cytotoxic or cytostatic effects, depending on individual characteristics of tumor cell lines. Five cell lines showed insensitivity against LBIF activity, suggesting a plausible involvement of LBIF receptor molecules to transduce LBIF signals. These results suggest that LBIF may play important roles in regulating cell growth.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2403840

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma.

Authors:  N Savaraj; M You; C Wu; M Wangpaichitr; M T Kuo; L G Feun
Journal:  Curr Mol Med       Date:  2010-06       Impact factor: 2.222

2.  Identification and purification of arginine deiminase that originated from Mycoplasma arginini.

Authors:  K Sugimura; S Fukuda; Y Wada; M Taniai; M Suzuki; T Kimura; T Ohno; K Yamamoto; I Azuma
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

3.  Cloning and nucleotide sequence of the gene encoding arginine deiminase of Mycoplasma arginini.

Authors:  T Ohno; O Ando; K Sugimura; M Taniai; M Suzuki; S Fukuda; Y Nagase; K Yamamoto; I Azuma
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

Review 4.  Pegylated arginine deiminase: a novel anticancer enzyme agent.

Authors:  Lynn Feun; Niramol Savaraj
Journal:  Expert Opin Investig Drugs       Date:  2006-07       Impact factor: 6.206

5.  A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients.

Authors:  T-S Yang; S-N Lu; Y Chao; I-S Sheen; C-C Lin; T-E Wang; S-C Chen; J-H Wang; L-Y Liao; J A Thomson; J Wang-Peng; P-J Chen; L-T Chen
Journal:  Br J Cancer       Date:  2010-08-31       Impact factor: 7.640

6.  Polymorphism in genes for the enzyme arginine deiminase among Mycoplasma species.

Authors:  K Sugimura; T Ohno; I Azuma; K Yamamoto
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

Review 7.  Arginine deprivation as a targeted therapy for cancer.

Authors:  L Feun; M You; C J Wu; M T Kuo; M Wangpaichitr; S Spector; N Savaraj
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

8.  Tumor necrosis factor (TNF) induces astrogliosis, microgliosis and promotes survival of cortical neurons.

Authors:  Ebtesam M Abd-El-Basset; Muddanna Sakkattu Rao; Solaiman M Alshawaf; Hasan Kh Ashkanani; Abdulaziz H Kabli
Journal:  AIMS Neurosci       Date:  2021-11-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.